Robert W. Baird Has Lowered Expectations for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its price objective reduced by equities researchers at Robert W. Baird from $645.00 to $575.00 in a research note issued on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s price target would indicate a potential upside of 25.52% from the stock’s current price.

ISRG has been the subject of a number of other research reports. TD Cowen upgraded shares of Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. Zacks Research lowered shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. HSBC lifted their price target on shares of Intuitive Surgical from $644.00 to $653.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Sanford C. Bernstein lifted their price target on shares of Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Finally, Barclays set a $712.00 price target on shares of Intuitive Surgical and gave the company an “overweight” rating in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $598.36.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $458.08 on Wednesday. The stock has a market cap of $162.68 billion, a P/E ratio of 58.06, a P/E/G ratio of 3.66 and a beta of 1.68. The firm has a 50 day moving average price of $479.59 and a 200 day moving average price of $514.26. Intuitive Surgical has a 52-week low of $427.84 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.21 earnings per share. Analysts predict that Intuitive Surgical will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Mark Brosius sold 645 shares of the business’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $485.01, for a total value of $312,831.45. Following the sale, the senior vice president owned 1,613 shares of the company’s stock, valued at $782,321.13. The trade was a 28.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Patricia L. Wadors sold 220 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $499.71, for a total transaction of $109,936.20. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 32,943 shares of company stock worth $17,279,568. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Intuitive Surgical

A number of institutional investors have recently made changes to their positions in ISRG. Brighton Jones LLC lifted its position in shares of Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after purchasing an additional 731 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Intuitive Surgical by 3.8% in the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 34 shares in the last quarter. Schnieders Capital Management LLC. lifted its position in shares of Intuitive Surgical by 38.0% in the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 268 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Intuitive Surgical in the second quarter worth $200,000. Finally, Main Street Financial Solutions LLC lifted its position in shares of Intuitive Surgical by 92.4% in the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock worth $1,592,000 after purchasing an additional 1,407 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Underlying procedure growth and da Vinci 5 roll-out remain key tailwinds that could support recurring instruments & accessories revenue and longer-term top-line expansion. Intuitive Surgical Pre-Q1 Analysis
• Positive Sentiment: Most sell-side analysts remain constructive (buy/outperform) and median price targets sit well above current levels, providing analyst support despite some recent downgrades to targets. Quiver Quantitative coverage of analysts and targets
• Neutral Sentiment: Investors are in a watch-and-wait mode ahead of Q1 — analysts and previews are focused on procedure volumes, system placements and consumable attach rates (key inputs that will drive the quarter’s guidance reaction). Seeking clues to Q1 earnings (Zacks)
• Neutral Sentiment: Competitive device news — e.g., an FDA clearance for a navigation-compatible SI-joint fusion system — is worth monitoring but is not an immediate threat to Intuitive’s core robotic surgery franchise. SurGenTec FDA 510(k) clearance
• Negative Sentiment: Regulatory safety headlines related to certain stapler/reload products compatible with da Vinci systems — including reports of serious injuries and a death cited in a U.S. regulator communication — have reintroduced headline risk and investor caution. Safety & cybersecurity overhangs (Quiver)
• Negative Sentiment: Earlier disclosed cybersecurity unauthorized access to parts of Intuitive’s internal administrative network (March disclosure) continues to weigh on sentiment even though surgical systems were not affected. Safety & cybersecurity overhangs (Quiver)
• Negative Sentiment: Price-target trims from some firms (Truist, Baird) plus a premium valuation multiple and noticeable insider/institutional selling episodes increase sensitivity to negative news and can pressure the stock ahead of earnings. Price target changes reported (Benzinga/MarketScreener/The Fly)

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.